Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.

@article{McGarry2020AdditionalSA,
  title={Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.},
  author={Andrew McGarry and Peggy Auinger and Karl D. Kieburtz and Michael Geva and Munish Mehra and Victor Abler and Igor D. Grachev and Mark Forrest Gordon and Juha Matti Savola and Sanjay K. Gandhi and Spyridon Papapetropoulos and Michael R. Hayden},
  journal={Journal of Huntington's disease},
  year={2020},
  volume={9 2},
  pages={
          173-184
        }
}
BACKGROUND Open-HART was an open-label extension of HART, a randomized, double-blind, placebo-controlled study of pridopidine in Huntington disease (HD). Previously, we reported safety and exploratory efficacy data after 36 months of treatment with pridopidine 45 mg twice daily. In the interim, emerging data suggests pridopidine may have neuroprotective effects mediated by sigma-1 receptor agonism. OBJECTIVE To report additional safety and exploratory efficacy data for continued open-label… 
State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease
TLDR
The authors recommend prospective, observational clinical effectiveness studies which can evaluate the long-term comparative effectiveness and safety of VMAT-2 inhibitors and antipsychotics in HD.
Emerging therapeutics in Huntington’s disease
TLDR
It is expected that growing knowledge about the pathophysiology of the underlying disease and constant advances in biotechnology will lead to therapies that have a meaningful impact in the lives of patients, their families, and those who care for them.
Current and Possible Future Therapeutic Options for Huntington’s Disease
TLDR
The efficacy of current HD treatments is discussed, the clinical trial progress of emerging potential HD therapeutics are explored and potential therapies in pre-clinical development are explored.
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
TLDR
The potential role of the sigma receptors and their ligands as part of a multi receptor approach in the treatment of degenerative diseases of the CNS and the development of multi-drug combinations to target multiple receptors is discussed.
Discovery of 3‐(2‐aminoethyl)‐thiazolidine‐2,4‐diones as a novel chemotype of sigma‐1 receptor ligands
TLDR
This study reports the discovery of a novel lead compound for S1R binding, based on the thiazolidine‐2,4‐dione nucleus, and explores hydrophobic groups of different sizes on both sides of the five‐membered ring scaffold guided by the crystal structure of S1 R.
ISSN: 2595-6825
TLDR
It can be identified, in general, that the association between cognitive decline and infratentorial brain neoplasms is due to the form of treatment normally suggested to deal with this disease.
Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases
TLDR
It is proposed that S1R agonists enable the disassembly of these cholesterol-enriched microdomains and the release of accumulated proteins such as ion channels, signaling receptors, and trophic factors from the ER.
Sigma receptors and neurological disorders
TLDR
In the present review, the roles of sigma receptors are discussed, especially in the central nervous system disorders, and related therapies.

References

SHOWING 1-10 OF 18 REFERENCES
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
TLDR
Pridopidine 45 mg BID was generally safe and tolerable in HD subjects over 36 months and TMS declined in a manner consistent with the known natural history of HD.
A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
TLDR
The overall results suggest that pridopidine may improve motor function in Huntington's disease and the 90 mg/day dosage appears worthy of further study.
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
TLDR
These data do not justify use of CoQ as a treatment to slow functional decline in HD, and Class I evidence that CoQ does not slow the progressive functional decline of patients with HD is provided.
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
TLDR
The theory of pridopidine as molecule with disease‐modifying properties in HD is supported and the idea of a valuable therapeutic strategy for effectively treating the disease is advanced.
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
TLDR
Since the newly identified pathways are downregulated in neurodegenerative diseases, including HD, these findings suggest that pridopidine may exert neuroprotective effects beyond its role in alleviating some symptoms of HD.
In vivo pharmacology of the dopaminergic stabilizer pridopidine.
Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
TLDR
At doses shown to elicit neurochemical and behavioral effects, pridopidine occupied a large fraction of sigma-1Rs and a negligible fraction of D2Rs and the characteristics of dopamine stabilizers may result from the combination of high s Sigma-1R and low D2R affinity.
...
...